Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Next-generation Phenotypic Antimicrobial Susceptibility Test Platform: Rapid Resultsand Comprehensive Menus - the Goal of This CRP Sbir Proposal Is to Fund Four Projects to Advance the Commercial Readiness of Selux’s Rapid, Comprehensive, Low-cost, Phenotypic Antibiotic Susceptibility Test (AST) System. Selux’s Next-generation Phenotyping (NGP) Platform Uniquely Enables Rapid Ast With Comprehensive Antimicrobial Menus of >50 Drugs at a Low Cost From Isolates and Positive Blood Culture Samples. Aims 1 and 2 Focus on Cost Reduction Projects Important for Early Customer Adoption. Aim 1 Comprises Analytical Studies to Support Multiplex Oral Panels and Aim 2 Is a DFM Redesign of the Analyzer Consumable Pack. Aims 3 and 4 Focuses on Work Necessary for Later Customer Adoption. Aim 3 Is a Yearlong Benchmarking Study That Will Compare Selux NGP Performance Against Legacy Ast Systems and Reference Methods. by Improving System Workflows and Benchmarking Ast Performance Across Legacy Systems CRP Funding Will Help Position Selux NGP as the Dominant Ast Platform of the Future.
Committed
$2.8 Million
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…